KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Profit After Tax (2017 - 2025)

Historic Profit After Tax for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $18.1 million.

  • Amneal Pharmaceuticals' Profit After Tax rose 5422.3% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.3 million, marking a year-over-year increase of 15771.37%. This contributed to the annual value of -$73.9 million for FY2024, which is 5162.76% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Profit After Tax of $18.1 million as of Q3 2025, which was up 5422.3% from $35.6 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Profit After Tax registered a high of $35.6 million during Q2 2025, and its lowest value of -$242.1 million during Q2 2022.
  • In the last 5 years, Amneal Pharmaceuticals' Profit After Tax had a median value of $11.8 million in 2024 and averaged -$13.6 million.
  • Within the past 5 years, the most significant YoY rise in Amneal Pharmaceuticals' Profit After Tax was 42881.91% (2023), while the steepest drop was 257662.51% (2023).
  • Amneal Pharmaceuticals' Profit After Tax (Quarter) stood at -$20.5 million in 2021, then surged by 118.42% to $3.8 million in 2022, then tumbled by 2576.63% to -$93.3 million in 2023, then soared by 112.78% to $11.9 million in 2024, then surged by 52.0% to $18.1 million in 2025.
  • Its last three reported values are $18.1 million in Q3 2025, $35.6 million for Q2 2025, and $24.6 million during Q1 2025.